Quinestrol pharmaceutical-grade API, designated by manufacturer code QN-API-01, is the 3-cyclopentyl ether of 17α-ethinylestradiol, CAS 152-43-2, molecular formula C25H32O2 and relative molecular mass 364.53. The material is a white to almost-white crystalline powder with negligible aqueous solubility; dissolution in ethanol, acetone and methylene chloride is consistent with a lipophilic steroid ether. The product is supplied for tablet, capsule, granule and injectable manufacture under oral and injectable dosage-form categories. The manufacturer’s specification is aligned with ICH Q6A, ICH Q3C and ICH Q3D and uses general pharmacopoeial methods: identification by IR absorption spectroscopy equivalent to Ph. Eur. 2.2.24, assay by HPLC, loss on drying by USP <731>, and residue on ignition by Ph. Eur. 2.4.14. Compendial monograph coverage for quinestrol is not uniform across all territories; the API specification therefore combines product-specific acceptance criteria with the cited general chapters to maintain batch-to-batch equivalence. Typical release criteria include assay 98.0–102.0% on dried basis, total related substances ≤1.0%, and water content ≤0.5% when tested by Karl Fischer titration. Particle size is controlled by laser diffraction, usually with D50 ≤15 µm and D90 ≤30 µm, unless the dosage form requires micronized grade with D90 ≤10 µm. The product is distinguished from technical-grade estrogen ethers by residual solvent control, elemental impurity documentation, endotoxin testing when designated for injectable use, and a stability-indicating analytical package.

What Limits Direct Compression and Capsule Filling of Low-Dose Quinestrol Blends?

Direct compression is limited by three interacting factors: low aqueous solubility, low dose strength, and the flow and compaction behaviour of the crystalline powder. When the active fraction is below 1% w/w of the tablet core, the API is micronized to a particle size of D90 ≤10 µm to support content uniformity under Ph. Eur. 2.9.40 or USP <905>. Micronization increases surface free energy and may promote agglomeration, so a staged blending sequence is used: a preblend of quinestrol with microcrystalline cellulose or lactose monohydrate is passed through a 0.5 mm screen, mixed in a bin blender with an intensifier bar for 10–15 min at 12–18 rpm, and then combined with the remaining filler. Colloidal silicon dioxide at 0.1–0.5% w/w is added as a flow aid, and magnesium stearate or sodium stearyl fumarate is added at 0.4–0.6% w/w as a lubricant. On a rotary tablet press with D-tooling, compression force is held at 8–15 kN and turret speed at 25–60 rpm; tablet hardness is adjusted between 40–70 N for immediate-release tablets. Excessive compression can increase disintegration time beyond the 15 min limit of USP <701>, especially because the hydrophobic API can retard water penetration. For capsule filling, a tamping pin or dosator capsule machine with fill weight variation ≤3% is used; bulk density is maintained at 0.45–0.60 g/mL by controlling the particle size distribution of the final blend. Published data for a given commercial blend is limited, and these parameters are starting points requiring factorial evaluation at pilot scale.

When the direct compression route fails to meet content uniformity, a wet granulation route is employed. In a high-shear granulator with impeller speed 100–150 rpm and chopper speed 800–1200 rpm, the dry blend is wet-massed for 2–4 min after adding an aqueous binder solution containing hydroxypropyl methylcellulose and 0.05–0.2% sodium lauryl sulfate. The wet mass is transferred to a fluid-bed dryer with inlet air temperature 50–60 °C and dried to granule moisture 1.5–2.5% w/w. The dried granule is screened through a 0.8–1.0 mm sieve and then lubricated with magnesium stearate 0.5% w/w. This granule is suitable for tablet compression and capsule filling; for capsule filling, the granule bulk density is adjusted to 0.5–0.6 g/mL to maintain fill weight variation within ±3%. Pilot-scale experience on a rotary tablet press with D-tooling indicates that compression force may need to be reduced to 6–10 kN after wet granulation because the granule is more compressible than the direct-compression blend. Batch-to-batch variation in incoming API particle size can shift content uniformity and tablet hardness, particularly when the particle size distribution of the API is not controlled at receipt.

Injectable product design employs a different set of constraints. Quinestrol cannot be prepared as a simple aqueous solution at therapeutic strength because the molecule has negligible aqueous solubility. An oil-based vehicle such as sesame oil, castor oil or medium-chain triglycerides is used when a prolonged-release intramuscular depot is required; co-solvent systems containing benzyl alcohol and benzyl benzoate are used for short-acting injectable preparations. The API is dissolved in the oil phase at 40–60 °C under nitrogen to limit oxidative degradation, and the solution is filtered through a 0.22 µm hydrophobic membrane. Terminal sterilisation at 121 °C for 15 min is acceptable only after vehicle and API compatibility has been demonstrated; otherwise, aseptic processing of pre-sterilised vehicle and dry-heat-treated API is used. Injectable-grade quinestrol is tested for bacterial endotoxins per Ph. Eur. 2.6.14 or USP <85>, visible and subvisible particulates per Ph. Eur. 2.9.19 or USP <790>, and sterility per Ph. Eur. 2.6.1 or USP <71>. Compatibility with Type I glass vials and halobutyl rubber closures is evaluated because lipophilic vehicles may extract stopper additives. For the granule dosage form, wet granulation with an aqueous binder containing hydroxypropyl methylcellulose and a small amount of sodium lauryl sulfate improves wettability and drug distribution; drying in a fluid-bed dryer at inlet air temperature 50–60 °C to granule moisture ≤2% w/w is typical, followed by screening through a 0.8 mm sieve.

When Quinestrol Replaces Ethinylestradiol in Oral Hormone Products

Replacement of ethinylestradiol with quinestrol alters the analytical control strategy and the formulation risk profile. Because quinestrol is the 3-cyclopentyl ether of 17α-ethinylestradiol, the molecule is more lipophilic and is metabolically converted to ethinylestradiol over a prolonged period. The HPLC method must resolve the parent ether from free ethinylestradiol and from related steroidal impurities; a C18 column with acetonitrile–phosphate buffer at pH 3.0 and UV detection at 280 nm is representative of a stability-indicating method. Dissolution testing in plain water is not meaningful because of low aqueous solubility. For method development, USP <711> apparatus II with 900 mL of 0.3–0.5% sodium lauryl sulfate in water at 37 °C and paddle speed 50 rpm is used. The formulation may require a wetting agent and a tighter granule particle size distribution because the cyclopentyl ether produces a more hydrophobic surface than ethinylestradiol. In low-dose tablets, the control of assay and content uniformity does not automatically transfer from an ethinylestradiol product; the sampling and acceptance limits are re-established under Ph. Eur. 2.9.40 or USP <905> using the same dose range. Published data comparing the dissolution and stability of the two APIs in identical excipient systems is limited, so pilot-scale bracketing studies are required before substituting one estrogen for the other.

On production-scale tablet lines, the main batch-to-batch variance arises not from the chemical assay but from the physical state of the API: crystal habit, agglomerate size, and surface energy. If the incoming API contains particles above 100 µm, direct compression can produce superpotent and subpotent tablets even when the blend assay is acceptable. Sieving or jet milling at the API manufacturer site is therefore standard. A pilot-scale rotary tablet press run using 0.3% magnesium stearate and 0.5% colloidal silicon dioxide produced acceptable content uniformity when tablet weight was kept above 80 mg; below this mass, the relative standard deviation increased because the active particles were not sufficiently distributed. This behaviour is comparable across low-dose steroid APIs but should be verified for each formulation because published data for quinestrol-specific blends is limited.

Residual Solvent, Elemental Impurity, and Packaging-Grade Control

The product is released with a residual solvent profile aligned with ICH Q3C and Ph. Eur. 5.4. Class 1 solvents such as benzene and carbon tetrachloride are absent or below the ICH Q3C limit; methylene chloride, when used in recrystallisation, is controlled at a maximum of 600 ppm. Class 3 solvents such as ethanol and acetone are limited to 0.5% w/w individually. Elemental impurities are assessed under ICH Q3D and Ph. Eur. 2.4.8 or USP <232> and USP <233>; palladium, platinum and nickel are evaluated when metal-catalysed hydrogenation or coupling reactions are used in the route. The API is packed in double low-density polyethylene bags inside an aluminium laminate bag with desiccant, in a fibre drum. Storage at 15–25 °C with protection from light is specified; long-term and accelerated stability data are generated under ICH Q1A(R2) conditions. Endotoxin testing is required for injectable-grade material, with a limit derived from the maximum daily dose; typical acceptance is ≤0.5 EU/mg when administered as a depot injection. The analytical package includes a stability-indicating HPLC assay and a related substances procedure capable of detecting oxidative degradation products; the method is qualified per ICH Q2(R2) for specificity, linearity, accuracy and precision.

Oxidative Degradation Is the Principal Stability Risk for Bulk Quinestrol

Quinestrol is susceptible to oxidative degradation at the steroid double bond and the ethynyl group in the presence of peroxides, light and trace metal ions. The stability-indicating HPLC method uses a C18 column, gradient elution from 35% to 75% acetonitrile in phosphate buffer at pH 3.0, and UV detection at 280 nm. The method separates quinestrol from ethinylestradiol and from total related substances. Forced degradation studies under 0.1 N HCl, 0.1 N NaOH, 3% hydrogen peroxide and UV light are used to demonstrate specificity; the degradation products are not necessarily identified but are tracked by relative retention time. The API is stored in a light-resistant container under nitrogen because oxygen accelerates the formation of oxidative impurities. The synthesis from ethinylestradiol involves etherification of the 3-phenolic hydroxyl group with a cyclopentyl electrophile under basic conditions, and the final crystallisation from ethanol or acetone removes polar impurities. The product is dried under vacuum at 40–50 °C to residual solvent limits. Published data for the precise process yield and impurity profile of a given commercial route is limited because route details are proprietary.

Differences from Other Estrogen APIs in Analytical and Formulation Practice

Quinestrol differs from ethinylestradiol and estradiol hemihydrate in route-dependent handling, analytical separation and release-rate expectations. The cyclopentyl ether elevates lipophilicity relative to the parent phenol, reduces aqueous dissolution rate and prolongs residence time following oral or intramuscular administration. This property is exploited for depot-type products but complicates dissolution testing and wetting. Ethinylestradiol is already poorly water soluble but is less hydrophobic than quinestrol; estradiol hemihydrate has a different crystalline hydrate and is typically formulated with a similar micronization approach. In HPLC systems, quinestrol elutes later than ethinylestradiol and estradiol under reversed-phase conditions, requiring a stronger organic modifier or longer gradient time. The following table summarises pharmaceutical differences relevant to specification setting and process design:

Published side-by-side data for quinestrol, ethinylestradiol and estradiol hemihydrate in identical excipient matrices is limited; process development therefore relies on the pharmacopoeial general chapters and pilot-scale bracketing studies rather than direct transfer from one estrogen to another.